We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+9.22%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$10.2B
AUM Growth
-$9.59M
Cap. Flow
-$234M
Cap. Flow %
-2.3%
Top 10 Hldgs %
76.44%
Holding
39
New
5
Increased
9
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$212M
2
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$97.2M
3
TERN
Terns Pharmaceuticals
TERN
+$55.2M
4
CELC icon
Celcuity
CELC
+$28.8M
5
AVTX icon
Avalo Therapeutics
AVTX
+$22M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$393M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$256M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$79.9M
4
PTCT icon
PTC Therapeutics
PTCT
+$52M
5
ORKA
Oruka Therapeutics
ORKA
+$40.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$21.4B
$1.56B 15.34%
2,630,000
+23,940
+0.9% +$11.9M
ASND icon
2
Ascendis Pharma A/S
ASND
$16.2B
$1.16B 11.39%
5,062,500
-48,611
-1% -$10.9M
MDGL icon
3
Madrigal Pharmaceuticals
MDGL
$11.7B
$952M 9.36%
1,818,181
+10,681
+0.6% +$5.1M
KRYS icon
4
Krystal Biotech
KRYS
$9.76B
$746M 7.34%
2,888,888
– –
ARGX icon
5
argenx
ARGX
$53.1B
$730M 7.18%
1,000,000
+10,000
+1% +$7.83M
ARWR icon
6
Arrowhead Research
ARWR
$12.3B
$671M 6.6%
10,699,999
+74,999
+0.7% +$4.75M
KYMR icon
7
Kymera Therapeutics
KYMR
$9.66B
$623M 6.12%
7,474,747
– –
APLS
8
DELISTED
Apellis Pharmaceuticals
APLS
$492M 4.84%
12,222,222
– –
CNTA
9
DELISTED
Centessa Pharmaceuticals
CNTA
$454M 4.47%
11,430,455
-3,125,100
-21% -$79.9M
CELC icon
10
Celcuity
CELC
$4.48B
$385M 3.79%
3,375,000
+263,889
+8% +$28.8M
XENE icon
11
Xenon Pharmaceuticals
XENE
$6.03B
$336M 3.31%
5,777,777
+353,333
+7% +$16.3M
GPCR icon
12
Structure Therapeutics
GPCR
$3.8B
$316M 3.11%
6,555,555
– –
TERN
13
DELISTED
Terns Pharmaceuticals
TERN
$300M 2.95%
5,695,000
+1,345,000
+31% +$55.2M
VERA icon
14
Vera Therapeutics
VERA
$2.28B
$237M 2.33%
5,888,888
– –
RVMD icon
15
Revolution Medicines
RVMD
$43.5B
$228M 2.24%
2,344,444
+174,444
+8% +$17.6M
CYTK icon
16
Cytokinetics
CYTK
$10.3B
$220M 2.16%
+3,333,333
New +$212M
OCUL icon
17
Ocular Therapeutix
OCUL
$2.16B
$104M 1.03%
12,315,000
+1,537,223
+14% +$14.7M
DMRA
18
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.9B
$98M 0.96%
+3,783,000
New +$97.2M
QURE icon
19
uniQure
QURE
$3.28B
$97.4M 0.96%
5,959,595
-190,405
-3% -$3.86M
TSHA icon
20
Taysha Gene Therapies
TSHA
$1.86B
$97M 0.95%
21,700,000
– –
DFTX
21
Definium Therapeutics
DFTX
$5.7B
$94.5M 0.93%
5,000,000
– –
SLNO
22
DELISTED
Soleno Therapeutics
SLNO
$77M 0.76%
2,300,000
-600,000
-21% -$23.5M
ALKS icon
23
Alkermes
ALKS
$8.26B
$42.4M 0.42%
1,200,000
-200,000
-14% -$6.2M
SEPN
24
Septerna Inc
SEPN
$2.08B
$32.1M 0.32%
1,337,500
– –
VRDN icon
25
Viridian Therapeutics
VRDN
$2.49B
$29.3M 0.29%
1,500,000
– –
1
2

Similar funds

BHCM
Brevan Howard Capital Management St. Helier, Jersey $11.3B AUM 35.84% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
UE
Unisphere Establishment Vaduz, Liechtenstein $11.9B AUM 6.1% 1-Year Est. Return
PIF
Public Investment Fund Al Aqiq District, Riyadh, Saudi Arabia $12B AUM 0.61% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $9.71B AUM 26.27% 1-Year Est. Return

Avoro Capital Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Avoro Capital Advisors held 39 positions worth $10.2B, down 0.09% from $10.2B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Avoro Capital Advisors's Q1 2026 filing shows 5 new, 9 increased, 7 reduced and 7 closed positions. Its largest new stake was Cytokinetics: 3,333,333 shares worth $220M. The largest sale was Avidity Biosciences, an estimated $393M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

  • Avoro Capital Advisors's largest Q1 2026 buy was Cytokinetics: 3,333,333 shares worth $220M.
  • Avoro Capital Advisors added most to Terns Pharmaceuticals in Q1 2026, an estimated $55.2M increase.
  • Avoro Capital Advisors's biggest Q1 2026 reduction was Centessa Pharmaceuticals, cutting an estimated $79.9M.
  • Avoro Capital Advisors fully exited Avidity Biosciences in Q1 2026, selling an estimated $393M.
  • Avoro Capital Advisors's ten largest holdings make up 76% of its $10.2B portfolio in Q1 2026.
  • Avoro Capital Advisors opened 5 new positions and closed 7 in Q1 2026.
  • Avoro Capital Advisors's portfolio value fell 0.09% quarter-over-quarter to $10.2B.

Based on Avoro Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.